Pricing Log in Create free account

Kailera Therapeutics, Inc. (KLRA) vs Mesoblast Limited (MESO)

Kailera Therapeutics, Inc. and Mesoblast Limited are both Biotechnology companies. Kailera Therapeutics, Inc. and Mesoblast Limited are of similar size ($1.7B and $1.7B). Kailera Therapeutics, Inc. has the higher net margin (0.00% vs −1,091.7%) and the lower return on invested capital (−182.9% vs 0.00%). Across the 11 metrics below, Kailera Therapeutics, Inc. leads on 6 and Mesoblast Limited on 5.

Valuation

Metric KLRA MESO Biotechnology median
P/E n/m n/m 11.36
P/S n/m 136.96 9.12
P/B 1.67 1.79 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales n/m 136.55 8.56
Earnings yield 643,613,520.09% (8.48%) (34.18%)
Free cash flow yield (18.88%) (8.21%) (23.62%)

Profitability

Metric KLRA MESO Biotechnology median
Gross margin — (269.72%) 67.24%
Operating margin 0.00% (826.28%) 0.00%
Net margin 0.00% (1,091.71%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (85.74%) 0.00% (50.28%)
Return on assets (55.25%) 0.00% (45.89%)
Return on invested capital (182.92%) 0.00% 0.00%

Growth

Metric KLRA MESO Biotechnology median
Revenue growth (TTM) — (26.54%) 6.96%
EPS growth (last fiscal year) — 48.24% 29.86%
Revenue growth, 5-year CAGR — 74.39% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KLRA MESO Biotechnology median
Debt to equity 0.00 0.22 0.00
Current ratio 21.84 1.58 4.72
Net debt to EBITDA 3.46 (0.67) 1.01

Dividend

Metric KLRA MESO Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric KLRA MESO Biotechnology median
Market cap 1.72b 1.70b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack